C

Cuorips Inc
TSE:4894

Watchlist Manager
Cuorips Inc
TSE:4894
Watchlist
Price: 4 715 JPY -0.53% Market Closed
Market Cap: 37.9B JPY
Have any thoughts about
Cuorips Inc?
Write Note

Cuorips Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cuorips Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
Cuorips Inc
TSE:4894
Total Liabilities & Equity
ÂĄ6.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Total Liabilities & Equity
ÂĄ62.7B
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
25%
PeptiDream Inc
TSE:4587
Total Liabilities & Equity
ÂĄ93.4B
CAGR 3-Years
50%
CAGR 5-Years
38%
CAGR 10-Years
32%
Takara Bio Inc
TSE:4974
Total Liabilities & Equity
ÂĄ125.3B
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
7%
Pharma Foods International Co Ltd
TSE:2929
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
3%
CAGR 5-Years
30%
CAGR 10-Years
24%
S
StemRIM Inc
TSE:4599
Total Liabilities & Equity
ÂĄ9.1B
CAGR 3-Years
-6%
CAGR 5-Years
28%
CAGR 10-Years
N/A
No Stocks Found

Cuorips Inc
Glance View

Market Cap
37.8B JPY
Industry
Biotechnology

Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 46 full-time employees. The company went IPO on 2023-06-27. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The firm provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The firm operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

Intrinsic Value
234.89 JPY
Overvaluation 95%
Intrinsic Value
Price
C

See Also

What is Cuorips Inc's Total Liabilities & Equity?
Total Liabilities & Equity
6.2B JPY

Based on the financial report for Mar 31, 2024, Cuorips Inc's Total Liabilities & Equity amounts to 6.2B JPY.

What is Cuorips Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 1Y
72%

Over the last year, the Total Liabilities & Equity growth was 72%.

Back to Top